Thinle Chodon

7.4k citations

33 papers · 5.4k · 3 hit papers · h-index 22

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 18
- CAR-T cell therapy research 11
- Cancer Immunotherapy and Biomarkers 3
- HER2/EGFR in Cancer Research 3
Molecular Biology 13
- Melanoma and MAPK Pathways 7

Co-authors: Antoni Ribas (21 shared papers)Richard C. Koya (24 shared papers)Hubing Shi (4 shared papers)Xiangju Kong (4 shared papers)Roger S. Lo (4 shared papers)Jeffrey A. Sosman (3 shared papers)Hane Lee (2 shared papers)Stanley F. Nelson (2 shared papers)
Journals: Journal of Immunotherapy (4 papers)Clinical Cancer Research (3 papers)Journal for ImmunoTherapy of Cancer (3 papers)Cancer Discovery (3 papers)Cancer Research (2 papers)
Partner nations: United States Australia Japan

In The Last Decade

Thinle Chodon

33 papers receiving 5.4k citations

Thinle Chodon's Hit Papers

align trajectories log scale

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy 2013 · 732 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Cancer Discovery
2012 Nature Communications
2010 Nature

Peers

Countries citing papers authored by Thinle Chodon

Since Specialization

Citations

This map shows the geographic impact of Thinle Chodon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thinle Chodon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thinle Chodon more than expected).

Fields of papers citing papers by Thinle Chodon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thinle Chodon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thinle Chodon. The network helps show where Thinle Chodon may publish in the future.

Co-authors

The 25 scholars most cited alongside Thinle Chodon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thinle Chodon Line = papers co-authored together Thinle Chodon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature ·Ramin Nazarian, Hubing Shi, Qi Wang, Xiangju Kong, Richard C. Koya, Hane Lee, Zugen Chen, Mi‐Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon, Stanley F. Nelson, Grant A. McArthur, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo Hit paper breakdown →	2010	1674
2	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Cancer Discovery ·Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo Hit paper breakdown →	2013	732
3	Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance Nature Communications ·Hubing Shi, Gatien Moriceau, Xiangju Kong, Mi‐Kyung Lee, Hane Lee, Richard C. Koya, Charles Ng, Thinle Chodon, Richard A. Scolyer, Kimberly B. Dahlman, Jeffrey A. Sosman, Richard Kefford, Georgina V. Long, Stanley F. Nelson, Antoni Ribas, Roger S. Lo Hit paper breakdown →	2012	487
4	A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells Nature Medicine ·Chao Ma, Rong Fan, Habib Ahmad, Qihui Shi, Begonya Comin-Anduix, Thinle Chodon, Richard C. Koya, Chao Liu, Gabriel A. Kwong, Caius G. Radu, Antoni Ribas, James R. Heath	2011	368
5	PD-1 Blockade Expands Intratumoral Memory T Cells Cancer Immunology Research ·Antoni Ribas, Daniel Sanghoon Shin, Jesse M. Zaretsky, Juliet Frederiksen, Andrew Cornish, Earl Avramis, Elizabeth Seja, Christine Kivork, Janet Siebert, Paula Kaplan‐Lefko, Xiaoyan Wang, Bartosz Chmielowski, John A. Glaspy, Paul C. Tumeh, Thinle Chodon, Dana Pe’er, Begoña Comı́n-Anduix	2016	313
6	CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire Clinical Cancer Research ·Lídia Robert, Jennifer Tsoi, Xiaoyan Wang, Ryan Emerson, Blanca Homet, Thinle Chodon, Stephen Mok, Rong Huang, Alistair J. Cochran, Begoña Comı́n-Anduix, Richard C. Koya, Thomas G. Graeber, Harlan Robins, Antoni Ribas	2014	293
7	Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma Clinical Cancer Research ·Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J. Wong, Lídia Robert, David Foulad, Michael Cerniglia, Bjoern Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Anduix, Antoni Ribas	2014	291
8	BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy Cancer Research ·Richard C. Koya, Stephen Mok, Nicholas Otte, Kevin J. Blacketor, Begonya Comin-Anduix, Paul C. Tumeh, Aspram Minasyan, Nicholas A. Graham, Thomas G. Graeber, Thinle Chodon, Antoni Ribas	2012	189
9	CTLA4 blockade increases Th17 cells in patients with metastatic melanoma Journal of Translational Medicine ·Erika von Euw, Thinle Chodon, Narsis Attar, Jason Jalil, Richard C. Koya, Begonya Comin-Anduix, Antoni Ribas	2009	148
10	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition Cancer Discovery ·Hubing Shi, Aayoung Hong, Xiangju Kong, Richard C. Koya, Chunying Song, Gatien Moriceau, Willy Hugo, Clarissa C. Yu, Charles Ng, Thinle Chodon, Richard A. Scolyer, Richard Kefford, Antoni Ribas, Georgina V. Long, Roger S. Lo	2013	135
11	The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations Clinical Cancer Research ·Begoña Comı́n-Anduix, Thinle Chodon, Hooman Sazegar, Douglas Matsunaga, Stephen Mock, Jason Jalil, Helena Escuin-Ordinas, Bartosz Chmielowski, Richard C. Koya, Antoni Ribas	2010	114
12	Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy Cancer Discovery ·Chao Ma, Ann Cheung, Thinle Chodon, Richard C. Koya, Zhongqi Wu, Charles Ng, Earl Avramis, Alistair J. Cochran, Owen N. Witte, David Baltimore, Bartosz Chmielowski, James S. Economou, Begonya Comin-Anduix, Antoni Ribas, James R. Heath	2013	114
13	Keratinocytes Promote Proliferation and Inhibit Apoptosis of the Underlying Fibroblasts: An Important Role in the Pathogenesis of Keloid Journal of Investigative Dermatology ·Emi Funayama, Thinle Chodon, Akihiko Oyama, Tsuneki Sugihara	2003	108
14	Keloid-Derived Fibroblasts Are Refractory to Fas-Mediated Apoptosis and Neutralization of Autocrine Transforming Growth Factor-β1 Can Abrogate this Resistance American Journal Of Pathology ·Thinle Chodon, Tsuneki Sugihara, Hiroharu H. Igawa, Emi Funayama, Hiroshi Furukawa	2000	104
15	Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses Proceedings of the National Academy of Sciences ·Richard C. Koya, Stephen Mok, Begoña Comı́n-Anduix, Thinle Chodon, Caius G. Radu, Michael I. Nishimura, Owen N. Witte, Antoni Ribas	2010	49
16	Active Immunotherapy of Cancer Immunological Investigations ·Thinle Chodon, Richard C. Koya, Kunle Odunsi	2015	40
17	MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro Clinical Immunology ·Swagatam Ray, Arvind Chhabra, Nitya G. Chakraborty, Upendra P. Hegde, David I. Dorsky, Thinle Chodon, Erika von Euw, Begonya Comin-Anduix, Richard C. Koya, Antoni Ribas, James S. Economou, Steven A. Rosenberg, Bijay Mukherji	2010	39
18	CXCR6 by increasing retention of memory CD8⁺ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer Journal for ImmunoTherapy of Cancer ·Ravikumar Muthuswamy, AJ Robert McGray, Sebastiano Battaglia, Wenjun He, Anthony Miliotto, Cheryl Eppolito, Junko Matsuzaki, Takemasa Tsuji, Richard C. Koya, Thinle Chodon, Brian D. Lichty, Protul Shrikant, Kunle Odunsi	2021	35
19	HSV-sr39TK Positron Emission Tomography and Suicide Gene Elimination of Human Hematopoietic Stem Cells and Their Progeny in Humanized Mice Cancer Research ·Eric H. Gschweng, Melissa McCracken, Michael L. Kaufman, Michelle Ho, Roger P. Hollis, Xiaoyan Wang, Navdeep Saini, Richard C. Koya, Thinle Chodon, Antoni Ribas, Owen N. Witte, Donald B. Kohn	2014	29
20	Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma PLoS ONE ·Begoña Comı́n-Anduix, Hooman Sazegar, Thinle Chodon, Douglas Matsunaga, Jason Jalil, Erika von Euw, Helena Escuin-Ordinas, Robert Balderas, Bartosz Chmielowski, Jesús Gómez-Navarro, Richard C. Koya, Antoni Ribas	2010	26

About Thinle Chodon

Thinle Chodon is a scholar working on Oncology, Molecular Biology, Immunology, Genetics and Pathology and Forensic Medicine, having authored 33 papers that have together received 5.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (11 papers), Immunotherapy and Immune Responses (8 papers), Melanoma and MAPK Pathways (7 papers), Virus-based gene therapy research (7 papers), Immune Cell Function and Interaction (5 papers), T-cell and B-cell Immunology (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Oncology (2.9k citations), Immunology (1.3k citations), Molecular Biology (3.2k citations), Cancer Research (422 citations) and Pathology and Forensic Medicine (501 citations). Thinle Chodon has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Antoni Ribas, Richard C. Koya, Hubing Shi, Xiangju Kong, Roger S. Lo, Jeffrey A. Sosman, Hane Lee, Stanley F. Nelson, Mi‐Kyung Lee and Narsis Attar. Their work appears in journals such as Journal of Immunotherapy, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Cancer Discovery and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Thinle Chodon

Impact in

Papers in i

In The Last Decade

Thinle Chodon

Thinle Chodon's Hit Papers

Peers

Countries citing papers authored by Thinle Chodon

Fields of papers citing papers by Thinle Chodon

All Works

About Thinle Chodon

Explore authors with similar magnitude of impact

Papers in